Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
Journal: Clinical pharmacokinetics
Published: May 08, 2024
Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling.
Journal: Journal of clinical pharmacology
Published: December 21, 2023
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 17, 2023
Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Journal: British journal of clinical pharmacology
Published: December 26, 2018
Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans.
Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: July 01, 2017
Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection.
Journal: Clinical and translational science
Published: February 16, 2017
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Journal: Journal of diabetes investigation
Published: January 15, 2016
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Journal: Clinical therapeutics
Published: October 21, 2015
A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
Journal: Clinical pharmacology in drug development
Published: September 24, 2015
Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: September 10, 2015
Last Updated: 09/26/2026